HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Enforcement On COVID-19 Consumer Health Fraud Circles Back To Ayurvedic Products

Executive Summary

Georgia firm promoted a product as interrupting “infection chain” of coronavirus. Total of fraudulent COVID-19 claims FDA’s found in consumer health space approaches 200.

You may also be interested in...



US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims

Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims. 

US Supplement Firm Warned About Phenibut After Failing To Pull PTSD, Detox, Anxiety Claims

Latest FDA warning to Chill6 doesn’t reference previous letter but lists larger number of violations along with more details about the problems. Agency also recently added salt scrub therapies to its list of products as marketed with fraudulent coronavirus treatment claims.

US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds

Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel